British Columbia to be first Canadian province to switch patients to biosimilars

TORONTO/MONTREAL (Reuters) – The Canadian province of British Columbia said on Monday that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million)over three years.

The new policy from the province’s PharmaCare program targets Janssen’s Remicade and Amgen’s Enbrel which treat arthritis, among other conditions, and Sanofi’s long-acting insulin Lantus. It is the first of its kind in a Canadian public plan and could pave the way for similar programs across the country.

Biologic drugs are large molecules made using biological processes, and they tend to be expensive. Biosimilars work in the same way as biologics, but unlike generics they are not identical to the drug they are copying.

“Biosimilars are a necessary step to ensure PharmaCare provides existing coverage for more people and funds new drugs well into the future,” said the British Columbia government in a statement.

In Canada, pharmacists cannot swap biosimilars in for their predecessors once patents expire, the way they can with generics. Doctors must specifically prescribe the biosimilar, and they have been slow to do that. European countries have been quicker to adopt the drugs.

Sanofi Canada said it was disappointed and regretted that BC “did not take the opportunity to find an alternative solution to preserve this treatment option.” Janssen and Amgen did not immediately respond to requests for comment.

Canadian law says provincial governments must cover medically necessary care by doctors, but prescription drugs are paid for through a patchwork of public and employer-based insurance plans.

While every province offers some drug coverage, it is often limited to the elderly or people with low incomes or exceedingly high drug costs. BC’s system is unusual because it covers most residents, with deductibles based on income.

BC said patients with some types of arthritis, diabetes and plaque psoriasis would have until Nov. 25, 2019, to switch to a biosimilar. After that, the original biologic drugs would only be covered for those indications under exceptional circumstances.

At the same time, BC announced that it would begin covering two newer biologics: Boehringer Ingelheim and Eli Lilly’s Jardiance, a diabetes drug, and Eli Lilly’s Taltz, which treats psoriatic arthritis.

The policy should benefit drugmakers with covered biosimilars: Merck, Sandoz, Pfizer and Eli Lilly.

Merck Canada lauded the step in a statement on Monday.

“The initiative could help save millions of dollars over the first three years, and could improve access to prescription drugs for patients in the province,” the company said

Pfizer said it supported a well-controlled switch from a reference biologic drug to a biosimilar in an approved indication.

“BC has taken an informed, inclusive and responsible approach to enhancing access to biosimilars…,” Pfizer said.

Most Canadian provinces have started limiting coverage of branded biologics for new patients, without forcing patients to switch. Even that has prompted backlash. Early this year, Janssen won a lawsuit against Quebec, forcing its public drug plan to resume coverage of Remicade for new patients.

Because the ruling was based on the procedure Quebec took dropping the drug, most expect it to have little impact outside Quebec. It’s not clear how it will affect future policy in the province, which has a public plan for all residents who lack private insurance.

A spokeswoman for Quebec’s Health Department said work was under way to “identify the best practices and measures that could be used to help biosimilars make up a greater part of the market,” but that it would be premature to say more.

($1 = 1.3440 Canadian dollars)

Reporting by Allison Martell, Editing by Rosalba O’Brien and Sonya Hepinstall


more recommended stories

  • Teleflex recalls breathing tubes worldwide after reports of 4 deaths

    (Reuters) – Teleflex Inc said on.

  • In border camps, Syrians rely on doctors in trucks and tents

    AZAZ, Syria (Reuters) – The Syrian.

  • Thailand bans pig imports from Laos after African swine fever outbreak

    BANGKOK (Reuters) – Thailand will ban.

  • FDA approves drug for loss of sexual desire in women

    (Reuters) – The U.S. drug regulator.

  • Missouri orders lone abortion clinic to close; judge keeps it open for now

    ST. LOUIS (Reuters) – Missouri health.

  • Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

    NEW YORK (Reuters) – Merck &.

  • Strobing stage lights could up risk of epileptic seizures

    (Reuters Health) – Flashing light effects.

  • Euthanasia law takes effect in Australia’s Victoria state

    MELBOURNE (Reuters) – Voluntary euthanasia became.

  • China to suspend pork imports from third Canadian firm as dispute with Ottawa deepens

    BEIJING (Reuters) – China will block.

  • U.S. records 22 new measles cases, bringing year’s total to 1,044

    (Reuters) – The United States recorded.

  • WHO likely to declare Ebola an international emergency: experts

    GENEVA (Reuters) – The World Health.

  • WHO panel decides not to declare international Ebola emergency

    GENEVA (Reuters) – A World Health.

  • U.S. drugmakers file lawsuit against requiring drug prices in TV ads

    FILE PHOTO: Used blister packets that.

  • Death toll from UK hospital listeria outbreak rises to five

    LONDON (Reuters) – The number of.

  • Female soldiers wanting to suppress periods face barriers

    (Reuters Health) – Military women wanting.

  • Chronic depression after heart attack tied to increased risk of death

    (Reuters Health) – Heart attack survivors.

  • North Korea steps up measures to prevent spread of African swine fever

    SEOUL (Reuters) – North Korea has.

  • Missouri’s only abortion clinic to stay open after injunction issued

    (Reuters) – The only abortion clinic.

  • China to tighten rules on foreigners using genetic material

    FILE PHOTO: A researcher inserts a.

  • Experimental drug delays type 1 diabetes onset in mid-stage trial

    (Reuters Health) – In people at.

  • Abbott device helps in cutting blood sugar in type 2 diabetics: study

    (Reuters) – Insulin-dependent patients with type.

  • USDA investigates unapproved GMO wheat found in Washington state

    CHICAGO (Reuters) – The U.S. Department.

  • As pressure for Afghan peace grows, drug threat remains

    KANDAHAR, Afghanistan (Reuters) – Mohammad Ahmadi,.

  • One in four Ebola cases undetected in Congo: WHO

    GENEVA (Reuters) – Roughly a quarter.

  • U.S. health agency cancels research contract involving use of fetal tissue

    (Reuters) – The Department of Health.

  • Many U.S. kids still eating laundry pods

    Many American children are still being.

  • Nipah virus resurfaces in India’s Kerala after killing 17 last year

    NEW DELHI (Reuters) – The deadly.

  • Therapy in the office: banks take mental health fight in-house

    LONDON (Reuters) – In ‘Billions’, a.

  • Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

    CHICAGO (Reuters) – AstraZeneca and Merck.

  • Novartis hopes Kisqali data will help narrow gap to blockbuster rival

    ZURICH (Reuters) – Novartis has released.

  • Missouri abortion clinic to stay open for now after court order

    ST. LOUIS (Reuters) – Missouri’s only.

  • South Korea braces for African swine fever outbreak after North Korea case

    SEOUL (Reuters) – South Korea readied.